Abstract
PI3K and CDK4/6 inhibitors (CDK4/6i) are targeted therapies approved to treat advanced breast cancer; CDK4/6is are more widely used. Here, we discuss trials that examine PI3K inhibitors with novel drug combinations, including a CDK4/6i, given data implicating the pathway in CDK 4/6 resistance.
Cite
CITATION STYLE
APA
Clark, A. S., Makhlin, I., & DeMichele, A. (2021). Setting the pick: Can PI3K inhibitors circumvent CDK4/6 inhibitor resistance? Clinical Cancer Research, 27(2), 371–373. https://doi.org/10.1158/1078-0432.CCR-20-3624
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free